# Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Canonical URL: https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress
Ticker: VERU
Company: Veru Inc
Source: Veru Inc
Published: 2026-05-13 10:30 EST
Original Source URL: https://ir.verupharma.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-13 10:30 EST — [Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress](https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-second-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress) — Source: Veru Inc
- 2026-05-06 12:30 EST — [Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th](https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-second-quarter-financial-results-on-may-13th) — Source: Veru
- 2026-03-09 12:30 EST — [Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-enrolls-first-patient-in-phase-2b-plateau-clinical-trial-of-enobosarm-and-semaglutide-combination-for-high-quality-weight-loss) — Source: Veru Inc
- 2026-02-19 13:30 EST — [Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/VERU/veru-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference) — Source: Veru Inc
- 2026-02-11 11:30 EST — [Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress](https://biopharmsignal.com/news/VERU/veru-reports-fiscal-2026-first-quarter-financial-results-and-clinical-program-progress) — Source: Veru Inc
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)